Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : Prilenia therapeutics
Deal Size : 568.0
Deal Type : Licensing Agreement
Ferrer and Prilenia Partner for Pridopidine Commercialization and Co-Development
Details : Under the licensing agreement, Ferrer will holds the right to develop TV-7820 (pridopidine) an orally administered sigma-1 receptor agonist. It is being evaluated for Huntington’s Disease.
Product Name : TV-7820
Product Type : Other Small Molecule
Upfront Cash : $90.8 million
April 28, 2025
Lead Product(s) : Pridopidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Prilenia therapeutics
Deal Size : 568.0
Deal Type : Licensing Agreement
Ferrer Advances Research into PSP with the Inclusion of the First Participant in a Trial
Details : FNP-223 is an orally administered small molecule drug candidate, which is currently being evaluated for the treatment of progressive supranuclear palsy.
Product Name : FNP-223
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Ferrer Advances Research on Progressive Supranuclear Palsy with Phase II
Details : FNP-223 is a small molecule oral tablet, which is being evaluated in the mid-stage clinical trial studies to slow the progression of Progressive Supranuclear Palsy.
Product Name : FNP-223
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2024
Lead Product(s) : VRG50635
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Verge Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Verge Genomics Partners with Ferrer To Co-Develop ALS Therapy VRG50635
Details : The collaboration aims to co-develop VRG50635, Verge’s potent PIKfyve inhibitor, for treating sporadic & familial amyotrophic lateral sclerosis in various regions, including Europe & Southeast Asia.
Product Name : VRG50635
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 25, 2024
Lead Product(s) : VRG50635
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Verge Genomics
Deal Size : Undisclosed
Deal Type : Collaboration
Ferrer Reports Top-Line Results from Phase III ADORE Study in ALS
Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : FNP122
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2024
Ferrer Extends their Clinical Study in Amyotrophic Lateral Sclerosis (ALS)
Details : FAB122 (edaravone) is an investigational once daily, oral, small molecule drug candidate, which is currently being evaluated for the treatment of amyotrophic lateral sclerosis.
Product Name : FNP122
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Asceneuron
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Product Name : ASN90
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Asceneuron
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : CNIC
Deal Size : Inapplicable
Deal Type : Inapplicable
The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction
Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.
Product Name : Polypill
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2022
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : CNIC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Ferrer has been appointed as the exclusive, worldwide distributor to commercialise Tyvaso (treprostinil) for the treatment of PH-ILD, a rare, serious and progressive disease without an approved treatment in Europe and many other part...
Product Name : Tyvaso
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 28, 2022
Lead Product(s) : Treprostinil Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : United Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : FNP122 as an oral formulation of edaravone in ALS patients. Edaravone is an antioxidant and free radical scavenger that has been shown to reduce excess oxidative stress and cell death1, playing an important role in the pathology of ALS.
Product Name : FNP122
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2021
Reset All
